Skip to main content
FDA advises on orphan drug submissions
10/18/2017

The challenges of orphan drug development require different clinical trial approaches, such as crossover studies and randomized withdrawal studies, officials of the FDA's Center for Drug Evaluation and Research said. They also stressed the importance of natural history studies and other preclinical preparation.

Full Story: